ibrutinib

Reni Benjamin of Raymond James maintains a Strong Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) after hosting an investor meeting with Charles Farber, a notable physician at the Summit Medical Group. Benjamin noted Farber's practice treats approximately 80 patients per week who suffer from...

H.C. Wainwright maintains Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) as it welcomes the company’s amendment of a cancer study called GENUINE. Under GENUINE, TG is studying Ublituximab in combination with Ibrutinib versus Ibrutinib alone in patients with previously treated high-risk...

For the first time in the new year, markets ended the day on a positive note. While it is only a few days in, markets appear to have started off 2014 on uncertain footing. Investors and traders found some positives in the U.S. trade deficit which fell to its lowest level in four years, an...